Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.

AIDS (London, England) - 30 Mar 2007

Haubrich Richard, Berger Dan, Chiliade Philippe, Colson Amy, Conant Marcus, Gallant Joel, Wilkin Timothy, Nadler Jeffrey, Pierone Gerald, Saag Michael, van Baelen Ben, Lefebvre Eric

Abstract excerpt

BACKGROUND: Agents for the treatment of HIV-1-infected patients with resistance to current antiretroviral (ART) drugs are needed. METHODS: TMC114-C202 was a randomized, partially blinded, dose-finding study in treatment-experienced HIV-1-infected patients with one or more primary protease inhibit...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4 Lymphocyte Count
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Drug Therapy, Combination

Share to HIV Infections

Share to HIV Protease Inhibitors

Share to Reverse Transcriptase Inhibitors

Share to Ritonavir

Source

Identifiers

PMID: 17413685
DOI: 10.1097/QAD.0b013e3280b07b47

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17413685-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.PMID 17413685Read ↗

Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.Semantic proximity Read ↗

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.Semantic proximity Read ↗

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.Semantic proximity Read ↗

96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.Semantic proximity Read ↗

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.Semantic proximity Read ↗

A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.Semantic proximity Read ↗

Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH StudySemantic proximity Read ↗

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.Semantic proximity Read ↗

Tipranavir: a ritonavir-boosted protease inhibitor.Semantic proximity Read ↗

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.Semantic proximity Read ↗

Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.